Purpose Erlotinib is a highly specific epidermal growth factor receptor (HER1/EGFR) tyrosine
kinase inhibitor. This phase II study of erlotinib in patients with HER1/EGFR-expressing non…

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib | NEJM Skip to main content
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …

The human epidermal growth factor receptor (HER1/EGFR) is dysregulated in many solid
tumors, making it an attractive target for anticancer therapy. A number of agents that target this …

COVID-19 in patients with cancer is associated with a significantly increased risk of case
fatality, suggesting the need for proactive strategies to reduce likelihood of infection and …

As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically
needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we determined a …

Bortezomib, a proteasome inhibitor, shows substantial anti-tumor activity in a variety of
tumor cell lines, is in phase I, II, and III clinical trials and has recently been approved for the …

BACKGROUND: Preclinical studies in animal models have demonstrated tumor regression
following intratumoral administration of an adenovirus vector containing wild-type p53 …

Learning Objectives After completing this course, the reader will be able to: Describe the
clinical and pathological characteristics of the cutaneous rash secondary to anti-EGFR therapy. …

Cetuximab is a monoclonal antibody that targets the human epidermal growth factor receptor
(EGFR). Although approved for use in EGFR-overexpressing advanced colorectal cancer, …

The use of epidermal growth factor receptor (EGFR) inhibitors in several epithelial tumors
has increased considerably in recent years. Currently, they are approved in non-small cell …